Search results
Showing 16 to 30 of 223 results for heart attack
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
This quality standard covers the organisation and delivery of emergency and acute medical care in the community and in hospital. It covers adults (16 and over) who seek, or are referred for, emergency NHS care for a suspected or confirmed acute medical emergency. It describes high-quality care in priority areas for improvement.
View quality statements for QS174Show all sections
Sections for QS174
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
Myocardial infarction: measurement of ejection fraction (IND75)
This indicator covers the proportion of patients with acute myocardial infarction with measurement of left ventricular ejection fraction before discharge. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG94
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.
This indicator covers the proportion of patients with acute myocardial infarction who were discharged on dual antiplatelet therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG95
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had coronary reperfusion therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG91
This indicator covers the time between call for help and balloon inflation for patients with ST segment elevation myocardial infarction (STEMI) undergoing reperfusion by primary percutaneous coronary intervention (PCI). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG93
This indicator covers admission rates due to myocardial infarction in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG60
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)
Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.
View recommendations for HTG747Show all sections
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had balloon inflation for primary percutaneous coronary intervention (PCI) in less than 60 minutes from time of admission at a centre with primary PCI facilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG92